Valeant Pharmaceuticals has announced the formation of a new Patient Access and Pricing Committee that will be responsible for the pricing of the company's drugs Read more


Following Turing Pharmaceuticals’ famous 5,000% price hike on critical drug Daraprim, Canadian pharma group Valeant has followed up with a similarly incredulous move Read more


Valeant Pharmaceuticals International has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle Read more

Voice of concern: Re-revised proposal creates significant risks and uncertainties for Allergan stockholders, say industry experts Read more


Hot pursuit: Valeant Pharmaceuticals is continuing its pursuit to takeover Allergan. On Monday 12 May the American company Allergan, unanimously rejected the offer made by the Canadian company Read more